{
    "clinical_study": {
        "@rank": "40114", 
        "arm_group": [
            {
                "arm_group_label": "Ibuprofen 5% topical gel BID", 
                "arm_group_type": "Experimental", 
                "description": "IBU BID (Treatment A)"
            }, 
            {
                "arm_group_label": "Placebo topical gel BID", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo BID (Treatment B)"
            }, 
            {
                "arm_group_label": "Ibuprofen 5% topical gel TID", 
                "arm_group_type": "Experimental", 
                "description": "IBU TID (Treatment C)"
            }, 
            {
                "arm_group_label": "Placebo topical gel TID", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo TID (Treatment D)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to compare the efficacy and safety of Ibuprofen 5% Topical\n      Gel versus placebo administered two or three times daily for the treatment of pain\n      associated with delayed onset muscle soreness following intense eccentric exercise of the\n      elbow flexor muscles."
        }, 
        "brief_title": "Topical Ibuprofen for Delayed Onset Mulscle Soreness", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Males or females, 18 to 65 years of age, who have not engaged in upper extremity fitness\n        activities for a minimum of 3 months prior to entry in the study; subjects must be willing\n        to refrain from use of pharmacologic or non pharmacologic treatments (ie, heat, ice,\n        massage) and other forms of soreness relief during the study\n\n        Exclusion Criteria:\n\n        Use of corticosteroids or short- or long-acting non-steroidal anti-inflammatory drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "205", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794923", 
            "org_study_id": "B3491010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ibuprofen 5% topical gel BID", 
                "description": "10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days", 
                "intervention_name": "IBU BID", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo topical gel BID", 
                "description": "10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days", 
                "intervention_name": "Placebo BID", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ibuprofen 5% topical gel TID", 
                "description": "10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days", 
                "intervention_name": "IBU TID", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo topical gel TID", 
                "description": "10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days", 
                "intervention_name": "Placebo TID", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Delayed onset muscle soreness", 
            "ibuprofen", 
            "topical"
        ], 
        "lastchanged_date": "April 11, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3491010&StudyName=Topical%20Ibuprofen%20for%20Delayed%20Onset%20Mulscle%20Soreness"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19145"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Placebo-controlled, Double-blind Evaluation of the Efficacy and Safety of Ibuprofen 5% Topical Gel for the Treatment of Delayed-onset Muscle Soreness of the Elbow Flexor Muscles", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "time weighted Sum of Muscle Soreness with Movement (change from baseline) over 0-24 hours post Dose 1 (SMSM0-24)", 
            "measure": "Muscle Soreness with Movement (change from baseline) over 0-24 hours post Dose 1", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose, hourly from Hours 1 through 12, and at Hour 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794923"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in the time weighted sum of muscle soreness with movement over 24-48 hours, 48-72 hours, and 0-72 hours, and the change from baseline in muscle soreness with movement at each assessment time point", 
                "measure": "Change from baseline in the time weighted sum of muscle soreness with movement", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours"
            }, 
            {
                "description": "Change from baseline in the time weighted sum of spontaneous muscle soreness over 0-24 hours, 24-48 hours, 48-72 hours, and 0-72 hours and the change from baseline in spontaneous muscle soreness at each assessment time point", 
                "measure": "Change from baseline in the time weighted sum of spontaneous muscle soreness", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours"
            }, 
            {
                "description": "Time weighted sum of muscle soreness relief over 0-24 hours, 24-48 hours, 48-72 hours, and 0-72 hours and the relief score at each assessment time point", 
                "measure": "Time weighted sum of muscle soreness relief", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours"
            }, 
            {
                "description": "Change from baseline in muscle stiffness at 24 hours", 
                "measure": "Change from baseline in muscle stiffness", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Subject Global Assessment of Medication at Hour 72", 
                "measure": "Subject Global Assessment of Medication", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "description": "Number of doses of rescue medication", 
                "measure": "Number of doses of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours"
            }, 
            {
                "description": "Percentage of subjects taking rescue medication", 
                "measure": "Percentage of subjects taking rescue medication", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours"
            }, 
            {
                "description": "Time to rescue medication following each dose", 
                "measure": "Time to rescue medication following each dose", 
                "safety_issue": "No", 
                "time_frame": "0-72 hours"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}